Cellectis Collaborates with Sanofi for Alemtuzumab to be Utilized in CART-Cell Trials

 Cellectis Collaborates with Sanofi for Alemtuzumab to be Utilized in CART-Cell Trials

Shots:

  • The companies enter into a supply agreement for Alemtuzumab to be used in Cellectis’ trials as a lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial to treat r/r ALL, and for UCART123 in AMELI-01 clinical trial to treat r/r AML but not for UCARTCS1 due to self-lymphodepleting activity
  • Sanofi will provide alemtuzumab for Cellectis’ clinical trials and plans to execute the commercial supply of alemtuzumab under pre-agreed financial conditions
  • Cellectis’ UCART22 and UCART123 candidate have the CD52 gene inactivated by TALENT gene-editing technology while Alemtuzumab is an anti-CD52 monoclonal Ab

Click here to­ read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Cellectis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post